673 related articles for article (PubMed ID: 21208974)
1. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
[TBL] [Abstract][Full Text] [Related]
3. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
Buysse JM; Huang IZ; Pitt B
Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
[TBL] [Abstract][Full Text] [Related]
4. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
[TBL] [Abstract][Full Text] [Related]
5. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
7. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
[TBL] [Abstract][Full Text] [Related]
8. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
10. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
[TBL] [Abstract][Full Text] [Related]
12. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
13. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
[TBL] [Abstract][Full Text] [Related]
14. Race influences the safety and efficacy of spironolactone in severe heart failure.
Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
[TBL] [Abstract][Full Text] [Related]
15. Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials.
Piña IL; Yuan J; Ackourey G; Ventura H
Prog Cardiovasc Dis; 2020; 63(5):656-661. PubMed ID: 33007353
[TBL] [Abstract][Full Text] [Related]
16. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E
JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631
[TBL] [Abstract][Full Text] [Related]
17. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
[TBL] [Abstract][Full Text] [Related]
18. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
[TBL] [Abstract][Full Text] [Related]
19. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN
Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312
[TBL] [Abstract][Full Text] [Related]
20. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Agarwal R; Rossignol P; Romero A; Garza D; Mayo MR; Warren S; Ma J; White WB; Williams B
Lancet; 2019 Oct; 394(10208):1540-1550. PubMed ID: 31533906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]